Aethlon medical signs collaboration agreement with 34 lives to evaluate the ability of the hemopurifier® to expand the utility of unused, donated kidneys for transplant

Proof-of-concept studies to support the use of the hemopurifier  in the ex vivo organ perfusion circuit san diego, july 24, 2023 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has signed a collaboration agreement with 34 lives, pbc, to investigate the use of aethlon's proprietary hemopurifier® technology and 34 lives' organ evaluation and preservation system, with the goal of increasing the supply of useable donated kidneys for human transplant. financial terms of the agreement were not disclosed.
AEMD Ratings Summary
AEMD Quant Ranking